Born 1970. Chief Scientific Officer . Joined in 2020.
Professional background: Andreas Norlin has more than 25 years experience from research, preclinical- and clinical-stage drug development within e.g., oncology, inflammatory disease and diabetes. During the most recent years before joining Ascelia, Andreas had strategic executive roles in several biotech start-up companies in the Greater Copenhagen area. Before that he served as Project Vice President and held other development project leadership positions at Novo Nordisk, Denmark. Andreas started his career with various positions in preclinical R&D at Camurus AB, Sweden. Andreas joined Ascelia Pharma in 2020 as Project Director, Head of Preclinical. He is CSO and a member of the Management Team since 2022.
Education: Andreas has a M.Sc. in Biology and PhD in Animal Physiology from Lund University, Sweden. In addition, he has training within Drug Development Strategy and Medical Marketing from Copenhagen Business School.
Other ongoing assignments: Member of the Board of Directors for Apoglyx AB, Sweden and Desupervised ApS, Denmark. Founder of and Senior advisor at Xkout Bioscience AB.
Holdings in Ascelia: View holdings